{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001500","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.353168+00:00","generated_at":"2026-05-16T09:32:10.573272+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance","bullets":["22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.","Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.","PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.","One Merkel cell carcinoma patient had partial response; no disease progression in any patient."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001500","json":"https://secwatch.observer/filing/0001437749-26-001500.json","markdown":"https://secwatch.observer/filing/0001437749-26-001500.md","text":"https://secwatch.observer/filing/0001437749-26-001500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/0001437749-26-001500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/phio20260113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:32:10.573272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}